Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer

Eukaryotic elongation factor 2 kinase (eEF2K) is a CA²⁺/calmudulin-dependent protein kinase, belonging to a small family of an atypical Ser/Thr-protein kinase. eEF2K has been recently reported to be highly activated or overexpressed in many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target. In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivatives with assessment of inhibition activity against eEF2K and cytotoxicity. After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K inhibitor (21l) with best eEF2K enzymatic activity (IC₅₀ of 5.5 μM) and anti-proliferative activity (MDA-MB-231 cells, IC₅₀ of 12.6 μM, MDA-MB-436 cells, IC₅₀ of 19.8 μM). Moreover, we found that 21l could induce cell death via the apoptotic pathways in MDA-MB-231 and MDA-MB-436 cells. Subsequently, we evaluated its anti-tumor activity and apoptosis-inducing mechanisms in vivo. These results suggested that 21l inhibited tumor growth by Apoptosis in the xenograft mouse model of breast Cancer (MDA-MB-231 and MDA-MB-436). Collectively, our results demonstrate a novel small-molecule inhibitor targeting eEF2K with mechanism of Apoptosis and a therapeutic potential in breast Cancer.

Anti-tumor activity; Apoptosis; Breast cancer; Eukaryotic elongation factor 2 kinase; β-phenylalanine scaffold.